ARIXTRA for the treatment of pulmonary embolism

Once-daily ARIXTRA was as effective as a bolus plus continuous infusion of UFH in the treatment of PE [3]

Incidence of Symptomatic Recurrent VTE at 3 Months

ARIXTRA was well tolerated by patients undergoing treatment for PE [3]

Rates of Major Bleeding Were Similar During the Initial Treatment Period
*Bleeding was defined as major if it was clinically overt and associated with a decrease in hemoglobin of ≥2 units of packed red blood cells (PRBC) or whole blood, was retroperitoneal or intracranial, occurred in a critical organ, or contributed to death.

Study summary for the treatment of pulmonary embolism [3]

The MATISSE PE study evaluated the safety and efficacy of ARIXTRA (n=1,103) vs unfractionated heparin (UFH) (n=1,110) in the treatment of acute symptomatic PE. In both groups, treatment with a vitamin K antagonist (warfarin) was begun as soon as possible and within 72 hours after initiation of the study treatment and was continued for 3 months.

  • Sixteen percent of patients had cancer or a past history of cancer.
  • Fifteen percent of patients received at least some of the treatment outside of the hospital.

View Complete Prescribing Information for ARIXTRA for more information about this study.

Consider ARIXTRA for your at-risk patients.

CLICK HERE

Please see Important Safety Information and complete Prescribing Information, including BOXED WARNING
regarding epidural and spinal hematomas.